NCT00939146
- Conditions
- Cardiovascular Diseases, Chronic Disease, Death, +17 more
- Locations
-
- Duke University Medical Center Durham, North Carolina, United States
Clinical trial condition
Pulmonary Disease, Chronic Obstructive
Explore clinical trials studying Pulmonary Disease, Chronic Obstructive. Study availability and eligibility vary by location and protocol.
787 public trials
11 recruiting studies
Pulmonary Disease, Chronic Obstructive trial results
NCT00662805
- Conditions
- Chronic Disease, Disease Attributes, Lung Diseases, +5 more
- Locations
-
Not specified
NCT01072396
- Conditions
- Chronic Disease, Disease Attributes, Lung Diseases, +5 more
- Locations
-
- 205.440.1006 Boehringer Ingelheim Investigational Site Birmingham, Alabama, United States
- 205.440.1015 Boehringer Ingelheim Investigational Site Jasper, Alabama, United States
- 205.440.1002 Boehringer Ingelheim Investigational Site Torrance, California, United States
- 205.440.1018 Boehringer Ingelheim Investigational Site Hartford, Connecticut, United States
NCT00530842
- Conditions
- Chronic Disease, Disease Attributes, Lung Diseases, +5 more
- Locations
-
- 205.334.4309 Boehringer Ingelheim Investigational Site Gänserndorf, Austria
- 205.334.4308 Boehringer Ingelheim Investigational Site Hallein, Austria
- 205.334.4306 Boehringer Ingelheim Investigational Site Leoben, Austria
- 205.334.4301 Boehringer Ingelheim Investigational Site Linz, Austria
NCT00563381
- Conditions
- Chronic Disease, Disease Attributes, Lung Diseases, +5 more
- Locations
-
- 205.389.1020 Boehringer Ingelheim Investigational Site Feldbach, Austria
- 205.389.1010 Boehringer Ingelheim Investigational Site Feldkirch, Austria
- 205.389.1003 Boehringer Ingelheim Investigational Site Gänserndorf, Austria
- 205.389.1011 Boehringer Ingelheim Investigational Site Grimmenstein/Hochegg, Austria
Completed
Tiotropium In Exercise
NCT00525512
- Conditions
- Behavior, Chronic Disease, Disease Attributes, +8 more
- Locations
-
- 205.368.01023 Boehringer Ingelheim Investigational Site Jasper, Alabama, United States
- 205.368.01022 Boehringer Ingelheim Investigational Site Phoenix, Arizona, United States
- 205.368.01003 Boehringer Ingelheim Investigational Site Los Angeles, California, United States
- 205.368.01008 Boehringer Ingelheim Investigational Site Fort Collins, Colorado, United States
NCT00274573
- Conditions
- Chronic Disease, Disease Attributes, Lung Diseases, +5 more
- Locations
-
- Boehringer Ingelheim Investigational Site Aachen, Germany
- Boehringer Ingelheim Investigational Site Ahrensburg, Germany
- Boehringer Ingelheim Investigational Site Altenburg, Germany
- Boehringer Ingelheim Investigational Site Amberg, Germany
NCT00620516
- Conditions
- Chronic Disease, Disease Attributes, Lung Diseases, +5 more
- Locations
-
- Boehringer Ingelheim Investigational Site 1 Busan, South Korea
- Boehringer Ingelheim Investigational Site 2 Busan, South Korea
- Boehringer Ingelheim Investigational Site 3 Busan, South Korea
- Boehringer Ingelheim Investigational Site 4 Busan, South Korea
NCT00239499
- Conditions
- Chronic Disease, Disease Attributes, Lung Diseases, +5 more
- Locations
-
- Tijger Trial Centre Bellville, South Africa
- Boehringer Ingelheim Investigational Site Bloemfontein, South Africa
- UCT Lung Institute Cape Town, South Africa
- Boehringer Ingelheim Investigational Site Cape Town, South Africa
Completed
Spiriva® Assessment of FEV1 (SAFE)
NCT00277264
- Conditions
- Chronic Disease, Disease Attributes, Lung Diseases, +5 more
- Locations
-
- Respiratory Research, Room 1742 Calgary, Alberta, Canada
- Boehringer Ingelheim Investigational Site Calgary, Alberta, Canada
- 4A-185, 7007-14 Street SW Calgary, Alberta, Canada
- Boehringer Ingelheim Investigational Site Edmonton, Alberta, Canada